Nine Masts Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Nine Masts Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43K	Buy	+14,018	New	+$43K	0.01%	165

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nine Masts Capital's STLN Position: Q1 2026 in Review

Nine Masts Capital opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 14,018 shares worth $43K. The stake represents 0.01% of the portfolio and ranks #165 among its holdings.

115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Nine Masts Capital held 14,018 shares of Starling Oncology Institute, Inc. Common Stock worth $43K as of Q1 2026.
Starling Oncology Institute, Inc. Common Stock was a new Nine Masts Capital position in Q1 2026.
Starling Oncology Institute, Inc. Common Stock made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #165 holding.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.